Drug intelligence / Profile preview

CAY10444

Development stage: Unknown
Lead developer: Cayman Chemical
Modality: Small Molecules
Administration: Intraperitoneal, Oral

Overview

CAY10444 (also known as BML-241) is a small molecule research compound that acts as a selective antagonist for the sphingosine-1-phosphate 3 (S1P3) receptor. It demonstrates selectivity for S1P3 over the S1P1 receptor and is used to inhibit S1P-induced increases in intracellular calcium. Developed by Cayman Chemical, CAY10444 is utilized as a laboratory tool to investigate the role of S1P3 signaling in various biological processes, including ischemia/reperfusion injury and the migration of malignant cells in glioblastoma multiforme. It is not intended for human use and is not currently being developed as a therapeutic agent by any pharmaceutical company.

Other names: 298186-80-8

Targets

S1PR2 (S1P receptor 2)P2RX4 (P2X Purinoceptor 4)ADRA1A (α1A)S1PR3 (Sphingosine 1-phosphate receptor 3)

Beyond the preview

Go deeper on CAY10444.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CAY10444.

Explore the full profile